GlassScriptPhysician profile
Safwan Hamwi
NPI 1396940656
$183,565.06
in general payments reported to CMS, 2019-2025
46 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $33K · 2021: $21K · 2022: $23K · 2023: $21K · 2024: $22K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $8,934 · Honoraria: $8,800 · Travel and Lodging: $2,537 · Consulting Fee: $90.53 · Education: $62.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,990.00 |
| Food and Beverage | $8,934.43 |
| Honoraria | $8,800.00 |
| Travel and Lodging | $2,536.67 |
| Consulting Fee | $90.53 |
| Education | $62.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $89,984.42 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $25,853.78 | 2019-2024 | Jardiance, Mounjaro, Baqsimi |
| Bayer Healthcare Pharmaceuticals INC. | $14,836.78 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $12,091.61 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $7,397.51 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $6,435.26 | 2019-2022 | |
| Zealand Pharma US, INC. | $6,049.87 | 2020-2021 | |
| Corcept Therapeutics | $4,181.28 | 2019-2025 | Korlym |
| Medtronic, INC. | $3,429.69 | 2021-2025 | Minimed 780g, Minimed 770g |
| Mannkind Corporation | $2,521.15 | 2019-2025 | Afrezza |
| Medtronic Minimed, INC. | $2,289.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,392.69 | 2019-2023 | Lokelma, Farxiga |
| Novo Nordisk INC | $1,324.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $713.06 | 2019-2023 | |
| Abbott Laboratories | $572.87 | 2019-2025 | Freestyle Libre 3, Id Now Instrument |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $461.76 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $437.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $410.23 | 2019-2023 | Spravato |
| Dexcom, INC. | $404.21 | 2019-2022 | |
| Valeritas, INC. | $310.83 | 2019 | |
| Amarin Pharma, INC. | $253.33 | 2020-2022 | |
| Lifescan, INC. | $249.05 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.06 | 2019-2023 | Cycloset |
| Sequel Med Tech, LLC | $206.92 | 2025 | Twiist |
| Amgen INC. | $184.68 | 2024-2025 | Tepezza, Repatha |
| Genzyme Corporation | $182.00 | 2019-2020 | |
| Abbvie INC. | $170.27 | 2019-2023 | |
| Shire North American Group INC | $154.21 | 2019 | |
| Intra-Sana Laboratories | $146.30 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Alkermes, INC. | $85.28 | 2019-2023 | Vivitrol |
| Amphastar Pharmaceuticals, INC. | $80.35 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $69.79 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $66.38 | 2023-2024 | Crysvita |
| Beta Bionics, INC. | $62.25 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $53.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.37 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $35.29 | 2025 | Yorvipath |
| Vanda Pharmaceuticals INC. | $31.65 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $24.15 | 2023 | Rexulti |
| Ascensia Diabetes Care US INC. | $23.40 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $22.26 | 2020 | |
| Philips North America LLC | $19.91 | 2024 | (Ck7) Extended Holter |
| Novartis Pharmaceuticals Corporation | $19.04 | 2024 | |
| Axsome Therapeutics, INC. | $18.13 | 2024 | Auvelity |
| Rhythm Pharmaceuticals, INC. | $17.35 | 2021 | |
| Teleflex LLC | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safwan Hamwi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.